naltrexone has been researched along with ribavirin in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dore, GJ | 1 |
| Bull, J; Chua, F; Galhenage, S; Hulse, G; Jeffrey, GP; MacQuillan, G; O'Neil, G; Young, E | 1 |
| Chung, HK; Lamb, K; Lin, MZ; Plemper, RK; Weisshaar, M; Yan, D | 1 |
| Marjakangas, JM; Overheul, GJ; Thomassen, MC; van Cleef, KW; van Rij, RP | 1 |
1 review(s) available for naltrexone and ribavirin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for naltrexone and ribavirin
| Article | Year |
|---|---|
Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants.
Topics: Adolescent; Adult; Antiviral Agents; Drug Implants; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Prospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2007 |
10 other study(ies) available for naltrexone and ribavirin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Enhancing hepatitis C treatment uptake and outcomes for injection drug users.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferons; Naltrexone; Narcotic Antagonists; Patient Compliance; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2007 |
Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens.
Topics: Animals; Antiviral Agents; Benzylidene Compounds; Cell Line; Coinfection; Dogs; Dose-Response Relationship, Drug; Feasibility Studies; Fenretinide; Genes, Reporter; High-Throughput Screening Assays; Humans; Influenza A virus; Luciferases, Firefly; Luciferases, Renilla; Naltrexone; Narcotic Antagonists; Neuraminidase; Respiratory Syncytial Viruses; Ribavirin; Virus Internalization; Virus Replication; Zanamivir | 2015 |
Escape Mutations in NS4B Render Dengue Virus Insensitive to the Antiviral Activity of the Paracetamol Metabolite AM404.
Topics: Acetaminophen; Antiviral Agents; Arachidonic Acids; Biotransformation; Dengue Virus; Drug Resistance, Multiple, Viral; Gene Expression; Genes, Reporter; HeLa Cells; Humans; Luciferases; Microbial Sensitivity Tests; Mutation; Naltrexone; Ribavirin; Viral Nonstructural Proteins; Virus Replication | 2016 |